Dr. Jianghua Tu, MD, PhD, is a Research Scientist at the University of Texas Health Science Center at Houston (UTHealth), affiliated with the Brown Foundation Institute of Molecular Medicine and the Texas Therapeutics Institute. She previously served as an Associate Professor of Pharmacology at Central South University in China. Her research focuses on oncology pharmacology, pharmacogenomics, and precision medicine, with particular emphasis on genetic polymorphisms affecting drug pharmacokinetics, efficacy, and safety.
She has made significant contributions to understanding cytochrome P450 enzymes, drug transporters, and drug–drug interactions, supporting the development of individualized therapeutic strategies. Her current work centers on antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs) targeting Wnt signaling–related pathways for cancer therapy.
Dr. Tu has published extensively in peer-reviewed journals, with her work widely cited internationally, including citations in academic books and clinical research platforms. She has served as Principal Investigator on National Natural Science Foundation of China (NSFC) grants and as a peer reviewer for multiple international journals and national funding agencies, reflecting her recognized expertise and leadership in the field.
Dr. Jianghua Tu, MD, PhD, is a Research Scientist at the University of Texas Health Science Center at Houston (UTHealth), affiliated with the Brown Foundation Institute of Molecular Medicine and the Texas Therapeutics Institute. She previously served as an Associate Professor of Pharmacology at Central South University in China. Her research focuses on oncology pharmacology, pharmacogenomics, and precision medicine, with particular emphasis on genetic polymorphisms affecting drug pharmacokinetics, efficacy, and safety.
She has made significant contributions to understanding cytochrome P450 enzymes, drug transporters, and drug–drug interactions, supporting the development of individualized therapeutic strategies. Her current work centers on antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs) targeting Wnt signaling–related pathways for cancer therapy.
Dr. Tu has published extensively in peer-reviewed journals, with her work widely cited internationally, including citations in academic books and clinical research platforms. She has served as Principal Investigator on National Natural Science Foundation of China (NSFC) grants and as a peer reviewer for multiple international journals and national funding agencies, reflecting her recognized expertise and leadership in the field.